Drug Type Small molecule drug |
Synonyms DSF-Cu, Dicopp, Disulfiram/copper gluconate + [2] |
Target |
Mechanism ADHs inhibitors(Alcohol dehydrogenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC12H22CuO14 |
InChIKeyOCUCCJIRFHNWBP-IYEMJOQQSA-L |
CAS Registry527-09-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Glioblastoma | Phase 2 | - | - | |
Recurrent Glioblastoma | Phase 1 | US | 09 Mar 2017 | |
Secondary malignant neoplasm of pancreas | Discovery | US | 17 Oct 2019 |
Phase 2 | 1 | AE Assessment+nab-paclitaxel+disulfiram/copper gluconate+Gemzar+Disulfiram+gemcitabine+Copper Gluconate (Nab-Paclitaxel/Gemcitabine + DSF/Cu) | ggjhuupqvj(wyeyputihw) = oylfgxsuur iajjkbdbjf (cwpdtfhykq, iwjdpdcibh - pkeybftufe) View more | - | 18 Oct 2023 | ||
AE Assessment+nab-paclitaxel+disulfiram/copper gluconate+Gemzar+Disulfiram+gemcitabine+Copper Gluconate (FOLFIRINOX +DSF/Cu) | ggjhuupqvj(wyeyputihw) = djarihhkpg iajjkbdbjf (cwpdtfhykq, kksqhxmvpy - vocslgkvmx) View more | ||||||
Phase 2 | 23 | Temozolomide (TMZ)+Disulfiram/Copper | (hydastoorx) = bfcsbavjcz cqshwrntcd (xbeejwxrlz, npfyxryxja - wbwrsznnud) View more | - | 13 Sep 2021 |